Bristol-Myers Squib and Mount Sinai Innovation Partners have helped the cancer therapeutics developer complete its series B round.
US-based cancer therapeutics developer HiberCell has secured $67.4m in a series B round featuring Mount Sinai Innovation Partners, an investment and commercialisation firm for care provider Mount Sinai Health System, and pharmaceutical firm Bristol-Myers Squib.
The round also included Huizenga Capital Management, Monashee Investment Management, funds managed by Tekla Capital Management, Hercules Capital, Arch Venture Partners, Magnetic Ventures, Trinitas Capital and unnamed series A investors and undisclosed additional participants.
Alongside the series C financing, Hercules Capital provided HiberCell with a…
